NAS:ROIV Key Ratios
| Market Cap $ M | 25,071.83 |
| Enterprise Value $ M | 22,027.50 |
| P/E(ttm) | -- |
| PE Ratio without NRI | -- |
| Forward PE Ratio | -- |
| Price/Book | 5.93 |
| Price/Sales | 3,155.45 |
| Price/Free Cash Flow | -- |
| Price/Owner Earnings | -- |
| Payout Ratio % | -- |
| Revenue (TTM) $ M | 7.00 |
| EPS (TTM) $ | -0.53 |
| Beneish M-Score | -3.52 |
| 10-y EBITDA Growth Rate % | -- |
| 5-y EBITDA Growth Rate % | -5.60 |
| y-y EBITDA Growth Rate % | -- |
| EV-to-EBIT | -16.12 |
| EV-to-EBITDA | -16.15 |
| PEG | -- |
| Shares Outstanding M | 722.32 |
| Net Margin (%) | -3,534.96 |
| Operating Margin % | -18,146.12 |
| Pre-tax Margin (%) | -3,848.65 |
| Quick Ratio | 16.72 |
| Current Ratio | 16.72 |
| ROA % (ttm) | -5.05 |
| ROE % (ttm) | -6.12 |
| ROIC % (ttm) | -165.32 |
| Dividend Yield % | -- |
| Altman Z-Score | 39.70 |
ROIV Number of Guru Trades
ROIV Volume of Guru Trades
Gurus Latest Trades with NAS:ROIV
NAS:ROIV is held by these investors
Roivant Sciences Ltd Insider Transactions
Guru Commentaries on NAS:ROIV
Roivant Sciences is a commercial-stage biopharmaceutical company focused on developing and commercializing transformative medicines, primarily in inflammation and immunology. The manager highlights Roivant's potential for growth, indicating a positive outlook for the company as it operates in a sector with significant demand for innovative therapies. The addition of Roivant to the portfolio reflects a belief in its strong growth drivers and the ability to navigate through various macroeconomic environments.
New position Roivant, a biotechnology company developing therapies across a range of conditions, also supported results as investors recognized its repeatable in-licensing and drug development model. This model positions Roivant favorably in the market, as it allows for consistent innovation and potential revenue generation through strategic partnerships and acquisitions.
News about NAS:ROIV
Total 0- 1
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
